RxDoctor Payments Data

Yong Kim, MD

Family Medicine · Snellville, GANPI 1164452942

Payments from drug & device makers

$1,770in general payments, 2019–2025

Across 24 payments — averaging $73.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$325
  • Novo Nordisk$291
  • Sanofi-aventis U.S. LLC$209
  • Stryker$141
  • Axsome Therapeutics, Inc.$125
  • Gilead$123
  • plus $556 from 6 others

What the payments were for

  • Food & beverage$1,761100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,770 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$88,536
Medicare patients
210
Services billed
1,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide122$142,948
MounjaroTirzepatide53$62,514
EliquisApixaban33$34,735
XareltoRivaroxaban14$19,943
JardianceEmpagliflozin11$16,555
JanuviaSitagliptin Phosphate13$16,101
MyrbetriqMirabegron15$15,474
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$7,549
Spiriva RespimatTiotropium Bromide13$6,835
SymbicortBudesonide/Formoterol Fumarate18$6,093
Breo ElliptaFluticasone/Vilanterol12$4,868
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$3,314
ArexvyRsvpref3 Antigen/As01e/Pf12$3,284
Atorvastatin Calcium352$3,037
Gabapentin218$2,927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$291$142,948122 claims
Lilly USA, LLCMounjaro$325$62,51453 claims
Boehringer IngelheimJardiance, Spiriva Respimat$25$23,39124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Snellville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →